Pay in 4 interest-free payments of $7.13 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
In the key Phase 3 ATTAIN-1 trial published in the New England Journal of Medicine in 2025, once-daily orforglipron 36 mg produced mean body weight reductions of 11.2% at 72 weeks in adults with obesity, with nearly 55% of participants achieving at least 10% weight loss and 36% achieving 15% or more
Weight cycling and risk of gallstone disease in men
Impacts of protein quantity and distribution on body composition
MachadoJMinistroPCancelaEArajoRCastanheiraASilvaA
The sequencing data were uploaded to the Galaxy web platform (usegalaxy.org), and bioinformatics analysis was performed using the tools available on the public server (Afgan et al , 2016)
US$ 25.37
US$ 23.48
US$ 20.10
US$ 21.89
US$ 23.88
US$ 23.94
US$ 28.69
US$ 23.86
US$ 26.90
